financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 13, 2025 7:39 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

 

Millennium International Management LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Wood Group (John) plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

12th November 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

 

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

4 2/7p Ordinary (GB00B5N0P849)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

 

Purchase/sale

 

 

Number of securities

 

Price per unit (GBP)

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

 

Product description

e.g. CFD

 

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 

Number of reference securities

 

Price per unit

 

GB00B5N0P849

 

Equity Swap

 

Reducing a Long Position

 

183,459

 

0.23 GBP

GB00B5N0P849

 

Equity Swap

 

Reducing a Long Position

 

12,303

 

0.23 GBP

GB00B5N0P849

 

Equity Swap

 

Increasing a Long Position

 

12,303

 

0.21 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

 

Product description e.g. call option

 

Writing, purchasing, selling, varying etc.

 

Number of securities to which option relates

 

Exercise price per unit

 

Type

e.g. American, European etc.

 

Expiry date

 

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

 

Product description

e.g. call option

 

Exercising/ exercised against

 

Number of securities

 

Exercise price per unit

 

 

 

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

 

Nature of dealing

e.g. subscription, conversion

 

Details

 

Price per unit (if applicable)

 

 

 

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(c) Attachments

Class of relevant security:

 

4 2/7p Ordinary (GB00B5N0P849)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

0

Class of relevant security:

 

4 2/7p Ordinary (GB00B5N0P849)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

6,921,676

 

1.000%

 

146,493

 

0.021%

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at [email protected]. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Millennium Partners, L.P.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial
Sep 16, 2024
04:18 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Sunday a phase 3 trial of Keytruda in combination with chemotherapy before surgery and after surgery without chemotherapy showed improved overall survival rates in patients with high-risk early-stage triple-negative breast cancer. Among the 1,174 patients enrolled in the study, the patients treated with the Keytruda combination showed an...
Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results
Replimune Group Says Potential Melanoma Treatment Study Yielded Positive Results
Sep 16, 2024
04:39 AM EDT, 09/16/2024 (MT Newswires) -- Replimune Group ( REPL ) said Sunday that an analysis of a trial of its drug RP1 combined with nivolumab showed clinically meaningful and durable systemic anti-tumor activity in patients with anti-PD1 failed melanoma. The 140-patient study showed an overall response rate of 33.6%, meeting its primary endpoint, the company said. Price: 11.22,...
Italy's Marcolin to produce, distribute Abercrombie & Fitch glasses from 2025
Italy's Marcolin to produce, distribute Abercrombie & Fitch glasses from 2025
Sep 16, 2024
MILAN, Sept 16 (Reuters) - Italian eyewear maker Marcolin signed an exclusive multi-year licensing agreement with Abercrombie & Fitch ( ANF ) to produce and distribute sunglasses and optical frames for the US fashion retailer, the two companies said in a joint statement on Monday. Spring and summer collections - for the Abercrombie, abercrombie Kids and Hollister brands - will...
Italian private bank Banca Generali bids for broker Intermonte
Italian private bank Banca Generali bids for broker Intermonte
Sep 16, 2024
MILAN (Reuters) -Italian private bank Banca Generali on Monday said it was launching a 98 million euro ($109 mln) all-cash buyout bid for Intermonte, to take the Milanese broker private and direct its services at Banca Generali clients. Shares in Intermonte failed to start trading at the market open, and were last indicated up 19.6%, broadly in line with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved